Cleerly Coronary Analysis
Cleerly · Outpatient cardiology · Cloud analysis + physician review
Imaging & Diagnostic AI
AI-based coronary CT angiography quantification (plaque analysis) with a large outcomes-oriented evidence program (TRANSFORM trial) targeting heart-disease prevention.
Evidence at a glance
Freshness, source-checked counts, confidence and gate results below reflect the frozen evidence snapshot through . A later editorial review does not update these results.
- Stated intended users
- Cardiology practices, health systems, prevention programs
- Documentary gate at snapshot
- Failed
- Scenario match
- Matches this scenario — FDA-cleared imaging AI platforms
- Comparability
- Not yet comparable in this scenario
- Decision readiness at snapshot
- HISTORICAL — Research only
- Documented evidence at snapshot
- 0 of 2 evidence claims source-checked · confidence Low
- Critical unknowns
- No critical documentary gaps identified
- Latest checked-source retrieval in snapshot
- not yet measured
Expand each claim to inspect its source, dates and recorded verification status.
independent reportMedicare coverage pathway established via new CPT Category I codes for quantitative coronary plaque analysis (2026).2026-01-01
Exact claim. Medicare coverage pathway established via new CPT Category I codes for quantitative coronary plaque analysis (2026).
- Source
- ama-assn.org
- Type
- independent report
- Published
- 2026-01-01
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- deployment_traction
Independent source. Methodology and sample vary by report; read the underlying method.
Open ama-assn.orgpeer reviewed studyCERTAIN study (European Heart Journal - Cardiovascular Imaging, 2024): in 750 consecutive patients at 5 expert CCTA sites, Cleerly AI-QCT an…2024-06-01
Exact claim. CERTAIN study (European Heart Journal - Cardiovascular Imaging, 2024): in 750 consecutive patients at 5 expert CCTA sites, Cleerly AI-QCT analysis improved physicians' confidence two- to five-fold at every step of the care pathway, changed diagnosis or management in 57.1% (428) of patients (P<0.001), and reduced the need for downstream non-invasive and invasive testing by 37.1% (P<0.001) versus conventional visual CCTA interpretation.
- Source
- pmc.ncbi.nlm.nih.gov
- Type
- peer reviewed study
- Published
- 2024-06-01
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- evidence_strength
- Score contribution
- Feeds evidence strength
Peer-reviewed. Check population, setting, and applicability to your workflow before generalizing.
Open pmc.ncbi.nlm.nih.govVerified provider experience is not yet publishable. Fewer than five independent provider organizations have contributed eligible reviews. Reviewer mode is off. Experience never changes documentary scoring, freshness, or rank.
Buyer lenses — evidence-backed bands at snapshot (not a 0–100 rank)
Deployment, integration, data handling at snapshot
- Integration maturity
- announced — Announced or documented integration; marketplace listing not confirmed.
- EHR path
- DICOM/PACS, structured reporting to EHR
- FHIR / API
- UNKNOWN
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- SSO
- UNKNOWN
Why unknown
Why. Single-sign-on support is not documented in vendor or marketplace materials on file.
What would close it. Vendor security documentation or marketplace listing mentioning SSO/SAML/OIDC.
- PHI / BAA
- BAA; imaging + derived reports · BAA available
- Security attestations
- HIPAA
- FDA status
- CLEARED
- Pricing
- Not publicly listed
Technical provenance
snap_36bba25c577cbb44 · Evidence cutoff: 2026-08-27T04:05Z · Snapshot generated: 2026-10-21T19:39Z · build ffbf5c3
Forecast calibration is not in the public snapshot — shown as UNKNOWN rather than read from SQLite.
Known limitations
- Deployment traction is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Economic value evidence is UNKNOWN.
Why unknown
Why. No independently verifiable ROI claim (peer-reviewed, audited case, or independent benchmark) is on file.
What would close it. An audited implementation report or peer-reviewed study with payback/throughput numbers.